Marinomed: Mit IPO soll der Break Even erreicht werden / In “absehbarer Zukunft” keine Dividendenzahlungen geplant

Die Wiener Marinomed Biotech AG will mit dem geplanten Börsengang am Prime Market der Wiener Börse den Break Even erreichen.
(Orginal – Story lesen…)

This website stores some user agent data. These data are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to opt-out of any future tracking, a cookie will be set up in your browser to remember this choice for one year. I Agree, Deny
730